Skip to Content

Bexxar Dosimetric Side Effects

Generic Name: tositumomab

Note: This document contains side effect information about tositumomab. Some of the dosage forms listed on this page may not apply to the brand name Bexxar Dosimetric.

Applies to tositumomab: intravenous kit

Cardiovascular

Common (1% to 10%): Hypotension, vasodilation[Ref]

Dermatologic

Very common (10% or more): Rash, pruritus
Common (1% to 10%): Sweating[Ref]

Endocrine

Common (1% to 10%): Hypothyroidism[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain, nausea, vomiting, diarrhea, anorexia
Common (1% to 10%): Constipation, dyspepsia[Ref]

Hematologic

Very common (10% or more): Neutropenia, thrombocytopenia, anemia[Ref]

Hypersensitivity

Common (1% to 10%): Allergic (hypersensitivity) reactions (allergic reaction, facial edema, injection site hypersensitivity, anaphylactic reaction, laryngismus, serum sickness)
Postmarketing reports: Hypersensitivity reactions including fatal anaphylaxis[Ref]

Immunologic

Very common (10% or more): Positive serology for human anti-mouse antibodies (HAMA)[Ref]

Local

Frequency not reported: Infusion reactions[Ref]

Metabolic

Common (1% to 10%): Peripheral edema, weight loss[Ref]

Musculoskeletal

Very common (10% or more): Myalgia, arthralgia
Common (1% to 10%): Back pain, neck pain[Ref]

Nervous system

Common (1% to 10%): Dizziness, somnolence
Postmarketing reports: Axonal neuropathy leading to quadriparesis[Ref]

Oncologic

Common (1% to 10%): Secondary malignancies (non-melanoma skin, colorectal, head and neck, breast, lung, bladder, melanoma, gastric)
Frequency not reported: Secondary leukemia, myelodysplastic syndrome[Ref]

Other

Very common (10% or more): Asthenia, fever, infections, pain, chills, headache
Common (1% to 10%): Chest pain, serious infections (pneumonia, bacteremia, septicemia, bronchitis, skin infections)[Ref]

Respiratory

Very common (10% or more): Cough, pharyngitis, dyspnea, rhinitis
Common (1% to 10%): Pneumonia[Ref]

References

1. "Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab)." GlaxoSmithKline, Research Triangle Park, NC.

2. "Product Information. BexxarTherapy (tositumomab)." GlaxoSmithKline Inc, Oakville, IA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide